Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
Nishi Kothari, Richard Kim, Robert N Jorissen, Jayesh Desai, Jeanne Tie, Hui-Li Wong, Ian Farragher, Ian Jones, Fiona L Day, Shan Li, Anuratha Sakthinandeswaren, Michelle Palmieri, Lara Lipton, Michael Schell, Jamie K Teer, David Shibata, Timothy Yeatman, Oliver M Sieber, Peter Gibbs, Ben Tran
Acta Oncologica | TAYLOR & FRANCIS LTD | Published : 2015
BACKGROUND: Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. PATIENTS AND METHODS: Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by t..View full abstract
Awarded by National Institutes of Health under the Biostatistics and Cancer Informatics Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute
Awarded by NATIONAL CANCER INSTITUTE
We thank the Victorian Cancer BioBank for patient specimens (Australia). We also thank Total Cancer Care (R) enabled, in part, by the generous support of the DeBartolo Family, and we thank the many patients who so graciously provided data and tissue to the Total Cancer Care Consortium (United States). This work was originally presented at the 2014 Gastrointestinal Cancers Symposium. This work was supported by funding from Ludwig Cancer Research (to OMS, PG) and a NHMRC R.D. Wright Biomedical Career Development Fellowship (to OMS). This work was also supported by the National Institutes of Health [grant P30-CA76292] under the Biostatistics and Cancer Informatics Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute.